PE20190260A1 - Isoquinolin-3-il-carboxamidas, y preparacion y uso de las mismas - Google Patents

Isoquinolin-3-il-carboxamidas, y preparacion y uso de las mismas

Info

Publication number
PE20190260A1
PE20190260A1 PE2018002175A PE2018002175A PE20190260A1 PE 20190260 A1 PE20190260 A1 PE 20190260A1 PE 2018002175 A PE2018002175 A PE 2018002175A PE 2018002175 A PE2018002175 A PE 2018002175A PE 20190260 A1 PE20190260 A1 PE 20190260A1
Authority
PE
Peru
Prior art keywords
unsubstituted
compound
halide
alkenyl
alkyl
Prior art date
Application number
PE2018002175A
Other languages
English (en)
Spanish (es)
Inventor
Sunil Kumar Kc
Gopi Kumar Mittapalli
Brian Joseph Hofilena
Joseph Timothy Marakovits
Chandramouli Chiruta
Chi Ching Mak
Jianguo Cao
Original Assignee
Samumed Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed Llc filed Critical Samumed Llc
Publication of PE20190260A1 publication Critical patent/PE20190260A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2018002175A 2016-04-27 2017-04-27 Isoquinolin-3-il-carboxamidas, y preparacion y uso de las mismas PE20190260A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328210P 2016-04-27 2016-04-27
PCT/US2017/029797 WO2017189823A2 (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof

Publications (1)

Publication Number Publication Date
PE20190260A1 true PE20190260A1 (es) 2019-02-25

Family

ID=60157342

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018002175A PE20190260A1 (es) 2016-04-27 2017-04-27 Isoquinolin-3-il-carboxamidas, y preparacion y uso de las mismas

Country Status (19)

Country Link
US (5) US10508099B2 (enExample)
EP (2) EP3448838B1 (enExample)
JP (1) JP7023243B2 (enExample)
KR (1) KR102399206B1 (enExample)
CN (1) CN109311819B (enExample)
AR (1) AR108326A1 (enExample)
AU (1) AU2017258187B2 (enExample)
BR (1) BR112018072190A2 (enExample)
CA (1) CA3022044A1 (enExample)
CL (2) CL2018003050A1 (enExample)
CO (1) CO2018012655A2 (enExample)
IL (1) IL262495B (enExample)
MA (1) MA43605B1 (enExample)
MX (1) MX386319B (enExample)
PE (1) PE20190260A1 (enExample)
PH (1) PH12018502259A1 (enExample)
RU (1) RU2018141379A (enExample)
SG (2) SG10201914127PA (enExample)
WO (1) WO2017189823A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為RORγT調節劑之6-胺基吡啶-3-基噻唑
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
MA45122A (fr) * 2016-05-24 2019-04-10 Constellation Pharmaceuticals Inc Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
MA48994A (fr) 2017-03-30 2020-02-05 Hoffmann La Roche Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
CA3079188A1 (en) * 2017-10-17 2019-04-25 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
WO2019079626A1 (en) * 2017-10-19 2019-04-25 Samumed, Llc 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
WO2019084496A1 (en) 2017-10-27 2019-05-02 Samumed, Llc 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL- (HETEROARYL 5-CHAIN) CARBOXAMIDES, PREPARATION AND USE
US10653688B2 (en) 2017-10-27 2020-05-19 Samumed, Llc 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
EP3807261B1 (en) 2018-06-18 2022-07-13 Janssen Pharmaceutica NV Pyridinyl pyrazoles as modulators of roryt
EP3806958B1 (en) 2018-06-18 2022-09-07 Janssen Pharmaceutica NV 6-aminopyridin-3-yl pyrazoles as modulators of roryt
US11345666B2 (en) 2018-06-18 2022-05-31 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of RORγT
JP2021528405A (ja) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ.ベー. RORγtのモジュレータとしてのアミド置換チアゾール
JP7386841B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
MX2022002720A (es) * 2019-09-05 2022-08-10 Lunan Pharmaceutical Group Corp Inhibidor de magl, procedimiento de preparacion y uso del mismo.
AU2021293583A1 (en) * 2020-06-19 2023-01-19 Vanderbilt University Arylsulfonyl derivatives and their use as muscarinic acetylcholine receptor M5 inhibitors
WO2022093881A1 (en) * 2020-10-29 2022-05-05 Merck Sharp & Dohme Corp. N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
US20240327412A1 (en) * 2021-02-19 2024-10-03 Kalvista Pharmaceuticals Limited Factor xiia inhibitors
EP4408427A4 (en) * 2021-10-01 2025-10-15 Merck Sharp & Dohme Llc SYSTEM AND METHOD FOR STATIC AND DYNAMIC MRI COMPENSATION
IL313539A (en) * 2021-12-10 2024-08-01 Prothena Biosciences Ltd Methods for treating neurological disorders
TW202506660A (zh) * 2023-04-27 2025-02-16 美商塞普特納公司 Mrgprx2拮抗劑及其使用方法
KR20240162928A (ko) 2023-05-09 2024-11-18 주식회사 베노바이오 Bet 단백질을 저해하는 신규한 벤조사이오펜 유도체 및 이를 이용한 암 치료용 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
ES2131463B1 (es) * 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
CA2594963A1 (en) 2005-01-24 2006-07-27 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
US7998978B2 (en) * 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
WO2009023193A1 (en) 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
CA2770320A1 (en) * 2009-08-10 2011-02-17 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
DK2987487T3 (da) * 2009-08-10 2020-12-07 Samumed Llc Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf
RU2012146246A (ru) * 2010-03-31 2014-05-10 Актелион Фармасьютиклз Лтд Антибактериальные производные изохинолин-3-илмочевины
CA2817460A1 (en) 2010-12-17 2012-06-21 F. Hoffmann-La Roche Ag Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
EP3473099A1 (en) 2011-09-14 2019-04-24 Samumed, LLC Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
WO2013169793A2 (en) * 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
US9557993B2 (en) 2012-10-23 2017-01-31 Analog Devices Global Processor architecture and method for simplifying programming single instruction, multiple data within a register
MA39763A (fr) 2014-03-20 2017-01-25 Samumed Llc Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
WO2020006115A1 (en) 2018-06-26 2020-01-02 Betty Tam Methods of treating cancer using a clk inhibitor

Also Published As

Publication number Publication date
EP3448838A4 (en) 2019-12-25
EP3448838A2 (en) 2019-03-06
CL2018003050A1 (es) 2019-01-25
US11174244B2 (en) 2021-11-16
CA3022044A1 (en) 2017-11-02
PH12018502259A1 (en) 2019-06-10
MA43605B1 (fr) 2020-10-28
AU2017258187B2 (en) 2021-08-26
SG11201809310PA (en) 2018-11-29
US10556885B2 (en) 2020-02-11
MA43605A1 (fr) 2020-04-30
EP3943086A1 (en) 2022-01-26
US20180222887A1 (en) 2018-08-09
CL2019002067A1 (es) 2020-07-10
JP7023243B2 (ja) 2022-02-21
BR112018072190A2 (pt) 2019-02-12
RU2018141379A3 (enExample) 2020-08-13
CN109311819A (zh) 2019-02-05
RU2018141379A (ru) 2020-05-28
EP3448838B1 (en) 2021-08-11
SG10201914127PA (en) 2020-02-27
US11673881B2 (en) 2023-06-13
AU2017258187A1 (en) 2018-11-15
US20200339536A1 (en) 2020-10-29
IL262495A (en) 2018-12-31
MX386319B (es) 2025-03-18
WO2017189823A2 (en) 2017-11-02
KR102399206B1 (ko) 2022-05-17
US20180208580A1 (en) 2018-07-26
WO2017189823A3 (en) 2018-02-08
IL262495B (en) 2021-12-01
MX2018013173A (es) 2019-02-13
US20170313681A1 (en) 2017-11-02
AR108326A1 (es) 2018-08-08
US10287267B2 (en) 2019-05-14
US20230104155A1 (en) 2023-04-06
JP2019515931A (ja) 2019-06-13
US10508099B2 (en) 2019-12-17
KR20190012167A (ko) 2019-02-08
CO2018012655A2 (es) 2019-04-30
CN109311819B (zh) 2022-10-25

Similar Documents

Publication Publication Date Title
PE20190260A1 (es) Isoquinolin-3-il-carboxamidas, y preparacion y uso de las mismas
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
AR091247A1 (es) Procesos para producir ciertos 2-(piridin-3-il)tiazoles
PE20191153A1 (es) Moduladores de calpainas y usos terapeuticos de los mismos
PE20160995A1 (es) Inhibidores de syk
AR112774A1 (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
AR091246A1 (es) Procesos para producir 2-(piridin-3-il)tiazoles
EA201690879A1 (ru) Новое триазолопиридиновое соединение
NZ732649A (en) Picolinamides and related compounds
AR105774A1 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
PE20150877A1 (es) Composicion herbicida que tiene actividad herbicida mejorada
CO2018010787A2 (es) Compuesto de griseofulvina
PE20141201A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
EA201691150A1 (ru) Соединения изопропилтриазолопиридина
BR112018001816A2 (pt) “análogos de adamantil ureias como inibidores solúveis da epóxido hidrolase
EA201791671A1 (ru) 4-замещенные соединения бензоксаборола и их применение
EA201690847A1 (ru) Новые ингибиторы dgat2
AR101255A1 (es) Derivados de isoindolinona
AR043487A1 (es) Heterociclos fusionados de pirimidina y usos de los mismos
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica